Sumitomo Mitsui Trust Holdings, Inc. Nurix Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $156 Billion
- Q2 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 1,391,638 shares of NRIX stock, worth $14.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,391,638
Previous 755,970
84.09%
Holding current value
$14.4 Million
Previous $8.98 Million
76.5%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding NRIX
# of Institutions
174Shares Held
79.3MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$70.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$62.8 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$46.2 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$40.9 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$40.2 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $488M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...